Evaluating the impact of discharging premature newborns weighing less than 2 kilos
Assessment of the Impact of the Return Home of Premature Newborns With Intrauterine Growth Retardation Weighing Less Than 2 Kilos (Low Birth Weight) on Short- and Long-term Morbidity/Mortality
This study looks at how discharging premature newborns who weigh less than 2 kilos affects their health and survival, by gathering feedback from parents about their experiences.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 1 Month to 11 Years |
| Sex | All |
| Sponsor | Hôpital NOVO Academic / other |
| Locations | 1 site (Pontoise) |
| Trial ID | NCT06224764 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the short-term and long-term outcomes of premature newborns who weigh less than 2 kilos at the time of discharge from the neonatology department at Hôpital NOVO. It will involve collecting data through questionnaires from parents to understand the effects of early discharge on morbidity and mortality rates. The research focuses on the implications of current discharge criteria and the role of parental involvement and health worker support in the care of these vulnerable infants. The study will analyze data from newborns discharged between 2012 and 2024 to provide insights into the effectiveness of these practices.
Who should consider this trial
Good fit: Ideal candidates for this study are premature newborns born at less than 37 weeks of gestation who weigh less than 2 kg at discharge.
Not a fit: Patients who are transferred to another hospital before discharge or whose parents do not speak or understand French may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved discharge protocols for premature infants, potentially reducing morbidity and mortality rates.
How similar studies have performed: Other studies have shown success in evaluating discharge criteria for premature infants, indicating that this approach is supported by existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Premature newborn baby (born at less than 37 days' gestation) * Newborn baby with IUGR (Intra-Uterine Growth Retardation) * Newborn baby hospitalised in the neonatology department of the NOVO hospital - Pontoise site * Patient born between 01/01/2012 and 31/12/2024. * Newborn who has left the neonatology department or the Kangaroo Unit to return home weighing less than 2 kg. * Newborn beneficiary of a social security scheme or entitled person. Exclusion Criteria: * Newborn transferred to another hospital before discharge. * Refusal by one of the parents. * Parent does not speak or understand French.
Where this trial is running
Pontoise
- Resuscitation and neonatal medicine department - Hôpital NOVO - Pontoise site — Pontoise, France (Recruiting)
Study contacts
- Principal investigator: Dr Suzanne BORRHOMEE — Hôpital NOVO
- Study coordinator: Maryline DELATTRE
- Email: maryline.delattre@ght-novo.fr
- Phone: +3333130754131
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.